LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

BioCryst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

10.35 -0.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.28

Max

10.38

Pagrindiniai rodikliai

By Trading Economics

Pajamos

27M

32K

Pardavimai

14M

146M

Pelnas, tenkantis vienai akcijai

0

Pelno marža

0.022

Darbuotojai

580

EBITDA

22M

21M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+58.63% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

473M

2.3B

Ankstesnė atidarymo kaina

10.83

Ankstesnė uždarymo kaina

10.35

Naujienos nuotaikos

By Acuity

75%

25%

358 / 380 reitingas Healthcare

BioCryst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-13 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380 Million

2025-06-14 01:24; UTC

Įsigijimai, susijungimai, perėmimai

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

2025-06-13 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

2025-06-13 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

2025-06-13 23:09; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

2025-06-13 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

2025-06-13 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380M

2025-06-13 22:04; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Better Data Facilitate Investments In Oil Patch -- Market Talk

2025-06-13 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Outside Date Extended to July 3

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

2025-06-13 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets Mexico Approval for Viterra Deal

2025-06-13 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets China Approval for Viterra Deal

2025-06-13 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-13 20:45; UTC

Įsigijimai, susijungimai, perėmimai

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025-06-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025-06-13 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2025-06-13 19:12; UTC

Rinkos pokalbiai

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

2025-06-13 19:04; UTC

Rinkos pokalbiai

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

2025-06-13 18:54; UTC

Rinkos pokalbiai

Correction to Gold Settles Market Talk

2025-06-13 18:01; UTC

Rinkos pokalbiai

Gold Settles at Record High -- Market Talk

2025-06-13 17:40; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

2025-06-13 17:21; UTC

Rinkos pokalbiai

Dollar Index, Commodities Rise -- Market Talk

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Akcijų palyginimas

Kainos pokytis

BioCryst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

58.63% į viršų

12 mėnesių prognozė

Vidutinis 16.45 USD  58.63%

Aukščiausias 30 USD

Žemiausias 11 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioCryst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

10

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

358 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.